Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-023512
Filing Date
2025-08-13
Accepted
2025-08-13 16:30:49
Documents
65
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1129919
2 EX-31.1 ex31-1.htm EX-31.1 19087
3 EX-31.2 ex31-2.htm EX-31.2 18951
4 EX-32.1 ex32-1.htm EX-32.1 8553
5 EX-32.2 ex32-2.htm EX-32.2 8255
  Complete submission text file 0001641172-25-023512.txt   5801856

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ensc-20250630.xsd EX-101.SCH 42676
7 XBRL CALCULATION FILE ensc-20250630_cal.xml EX-101.CAL 47172
8 XBRL DEFINITION FILE ensc-20250630_def.xml EX-101.DEF 176803
9 XBRL LABEL FILE ensc-20250630_lab.xml EX-101.LAB 342551
10 XBRL PRESENTATION FILE ensc-20250630_pre.xml EX-101.PRE 279346
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 907438
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38306 | Film No.: 251212177
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)